Refractory Ventricular Tachycardia
0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Angeles TherapeuticsCA - Los Angeles
1 programStereotactic Ablative RadiotherapyN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
ThermedicalSaline Enhanced Radiofrequency
Angeles TherapeuticsStereotactic Ablative Radiotherapy
Clinical Trials (2)
Total enrollment: 131 patients across 2 trials
Saline Enhanced Radiofrequency (SERF) Needle Ablation for Refractory VT
Start: Aug 2025Est. completion: Jun 2027130 patients
N/ARecruiting
Stereotactic Ablative Radiotherapy for Refractory Ventricular Tachycardia
Start: Apr 2017Est. completion: Aug 20191 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 131 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.